3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
29
Ovarian Neoplasms
2
Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Locoregional Recurrence
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Granulosa cell tumor of the ovary
1
Endometrial Neoplasms
1
Carcinoma, Ductal
1
Breast Carcinoma In Situ
1
Anatomic Stage III Breast Cancer AJCC v8
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Carcinoma
1
Advanced Breast Cancer
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
exemestane
×
90 days
×
Clear all
No trials found.